<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_r9AWQg6">Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension</title>
				<funder ref="#_pUcxtWs">
					<orgName type="full">European Union</orgName>
				</funder>
				<funder>
					<orgName type="full">New York University Grossman School of Medicine</orgName>
				</funder>
				<funder>
					<orgName type="full">National Health and Medical Research Council</orgName>
					<orgName type="abbreviated">NHMRC</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100000925</idno>
				</funder>
				<funder ref="#_TKc3ynq">
					<orgName type="full">NHMRC European Union</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Ruben</forename><surname>Willems</surname></persName>
							<email>ruben.willems@ugent.be</email>
							<idno type="ORCID">0000-0001-8732-9455</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Interuniversity Center of Health Economic Research (ICHER) , department of Public Health and Primary Care , Ghent University , Ghent , Belgium.</note>
								<orgName type="department" key="dep1">Interuniversity Center of Health Economic Research (ICHER)</orgName>
								<orgName type="department" key="dep2">department of Public Health and Primary Care</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lieven</forename><surname>Annemans</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Interuniversity Center of Health Economic Research (ICHER) , department of Public Health and Primary Care , Ghent University , Ghent , Belgium.</note>
								<orgName type="department" key="dep1">Interuniversity Center of Health Economic Research (ICHER)</orgName>
								<orgName type="department" key="dep2">department of Public Health and Primary Care</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">George</forename><surname>Siopis</surname></persName>
							<idno type="ORCID">0000-0003-1407-0846</idno>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Food, Nutrition and Dietetics , School of Allied Health , Human Services and Sport , La Trobe University , Melbourne , Australia.</note>
								<orgName type="department" key="dep1">Department of Food, Nutrition and Dietetics</orgName>
								<orgName type="department" key="dep2">School of Allied Health</orgName>
								<orgName type="department" key="dep3">Human Services and Sport</orgName>
								<orgName type="institution">La Trobe University</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Institute for Physical Activity and Nutrition , Deakin University , Geelong , Victoria , Australia.</note>
								<orgName type="department">Institute for Physical Activity and Nutrition</orgName>
								<orgName type="institution">Deakin University</orgName>
								<address>
									<settlement>Geelong Victoria</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">George</forename><surname>Moschonis</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Department of Food, Nutrition and Dietetics , School of Allied Health , Human Services and Sport , La Trobe University , Melbourne , Australia.</note>
								<orgName type="department" key="dep1">Department of Food, Nutrition and Dietetics</orgName>
								<orgName type="department" key="dep2">School of Allied Health</orgName>
								<orgName type="department" key="dep3">Human Services and Sport</orgName>
								<orgName type="institution">La Trobe University</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rajesh</forename><surname>Vedanthan</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Population Health , NYU Grossman School of Medicine , New York , USA.</note>
								<orgName type="department">Department of Population Health</orgName>
								<orgName type="institution">NYU Grossman School of Medicine</orgName>
								<address>
									<settlement>New York</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jenny</forename><surname>Jung</surname></persName>
							<idno type="ORCID">0000-0002-1774-1177</idno>
							<affiliation key="aff4">
								<note type="raw_affiliation"><label>5</label> Maternal, Child and Adolescent Health Program , Burnet Institute , Melbourne , Australia.</note>
								<orgName type="department">Maternal, Child and Adolescent Health Program</orgName>
								<orgName type="institution">Burnet Institute</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dominika</forename><surname>Kwasnicka</surname></persName>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> NHMRC CRE in Digital Technology to Transform Chronic Disease Outcomes , Baker Heart and Diabetes Institute , Melbourne , Australia.</note>
								<orgName type="department">in Digital Technology to Transform Chronic Disease Outcomes</orgName>
								<orgName type="institution" key="instit1">NHMRC CRE</orgName>
								<orgName type="institution" key="instit2">Baker Heart and Diabetes Institute</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<note type="raw_affiliation"><label>7</label> Faculty of Psychology , SWPS University of Social Sciences and Humanities , Wroclaw , Poland.</note>
								<orgName type="department">Faculty of Psychology</orgName>
								<orgName type="institution">SWPS University of Social Sciences and Humanities</orgName>
								<address>
									<settlement>Wroclaw</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brian</forename><surname>Oldenburg</surname></persName>
							<affiliation key="aff5">
								<note type="raw_affiliation"><label>6</label> NHMRC CRE in Digital Technology to Transform Chronic Disease Outcomes , Baker Heart and Diabetes Institute , Melbourne , Australia.</note>
								<orgName type="department">in Digital Technology to Transform Chronic Disease Outcomes</orgName>
								<orgName type="institution" key="instit1">NHMRC CRE</orgName>
								<orgName type="institution" key="instit2">Baker Heart and Diabetes Institute</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><surname>D'antonio</surname></persName>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>8</label> Meteda S.r.l. , Roma , Italy.</note>
								<orgName type="institution">Meteda S.r.l</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sandro</forename><surname>Girolami</surname></persName>
							<affiliation key="aff7">
								<note type="raw_affiliation"><label>8</label> Meteda S.r.l. , Roma , Italy.</note>
								<orgName type="institution">Meteda S.r.l</orgName>
								<address>
									<settlement>Roma</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eirini</forename><surname>Agapidaki</surname></persName>
							<affiliation key="aff8">
								<note type="raw_affiliation"><label>9</label> Ministry of Health , Athens , Greece.</note>
								<orgName type="institution">Ministry of Health</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yannis</forename><surname>Manios</surname></persName>
							<idno type="ORCID">0000-0001-6486-114X</idno>
							<affiliation key="aff9">
								<note type="raw_affiliation"><label>10</label> Department of Nutrition and Dietetics , School of Health Science and Education , Harokopio University , Athens , Greece.</note>
								<orgName type="department" key="dep1">Department of Nutrition and Dietetics</orgName>
								<orgName type="department" key="dep2">School of Health Science and Education</orgName>
								<orgName type="institution">Harokopio University</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<note type="raw_affiliation"><label>11</label> Institute of Agri-food and Life Sciences , Hellenic Mediterranean University Research Centre , Heraklion , Greece.</note>
								<orgName type="department">Institute of Agri-food and Life Sciences</orgName>
								<orgName type="institution">Hellenic Mediterranean University Research Centre</orgName>
								<address>
									<settlement>Heraklion</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nick</forename><surname>Verhaeghe</surname></persName>
							<idno type="ORCID">0000-0001-9956-4970</idno>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> Interuniversity Center of Health Economic Research (ICHER) , department of Public Health and Primary Care , Ghent University , Ghent , Belgium.</note>
								<orgName type="department" key="dep1">Interuniversity Center of Health Economic Research (ICHER)</orgName>
								<orgName type="department" key="dep2">department of Public Health and Primary Care</orgName>
								<orgName type="institution">Ghent University</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Department of Population Health , NYU Grossman School of Medicine , New York , USA.</note>
								<orgName type="department">Department of Population Health</orgName>
								<orgName type="institution">NYU Grossman School of Medicine</orgName>
								<address>
									<settlement>New York</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_KY6rmwe">Cost effectiveness review of text messaging, smartphone application, and website interventions targeting T2DM or hypertension</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">29FC22ADA6374A283854D6612C52A5F1</idno>
					<idno type="DOI">10.1038/s41746-023-00876-x</idno>
					<note type="submission">Received: 27 February 2023; Accepted: 7 July 2023;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T09:33+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_fYQB9zd"><p xml:id="_QqZxHnd"><s xml:id="_TT47SCH">Digital health interventions have been shown to be clinically-effective for type 2 diabetes mellitus (T2DM) and hypertension prevention and treatment.</s><s xml:id="_e6td3Uw">This study synthesizes and compares the cost-effectiveness of text-messaging, smartphone application, and websites by searching CINAHL, Cochrane Central, Embase, Medline and PsycInfo for full economic or cost-minimisation studies of digital health interventions in adults with or at risk of T2DM and/or hypertension.</s><s xml:id="_cMQWR42">Costs and health effects are synthesised narratively.</s><s xml:id="_3Czwz8u">Study quality appraisal using the Consensus on Health Economic Criteria (CHEC) list results in recommendations for future health economic evaluations of digital health interventions.</s><s xml:id="_mxD2UN3">Of 3056 records identified, 14 studies are included (7 studies applied text-messaging, 4 employed smartphone applications, and 5 used websites).</s><s xml:id="_PW5Dm34">Ten studies are cost-utility analyses: incremental cost-utility ratios (ICUR) vary from dominant to €75,233/quality-adjusted life year (QALY), with a median of €3840/QALY (interquartile range €16,179).</s><s xml:id="_wjb5UGU">One study finds no QALY difference.</s><s xml:id="_vxxuZXY">None of the three digital health intervention modes is associated with substantially better cost-effectiveness.</s><s xml:id="_9cmEmPU">Interventions are consistently cost-effective in populations with (pre)T2DM but not in populations with hypertension.</s><s xml:id="_Q8zMmpm">Mean quality score is 63.0% (standard deviation 13.7%).</s><s xml:id="_Jq4j8vG">Substandard application of time horizon, sensitivity analysis, and subgroup analysis next to transparency concerns (regarding competing alternatives, perspective, and costing) downgrades quality of evidence.</s><s xml:id="_eNcDpbW">In conclusion, smartphone application, text-messaging, and website-based interventions are cost-effective without substantial differences between the different delivery modes.</s><s xml:id="_z5KgCJt">Future health economic studies should increase transparency, conduct sufficient sensitivity analyses, and appraise the ICUR more critically in light of a reasoned willingness-to-pay threshold.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="595.276" lry="790.866"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_XBpvFBF">INTRODUCTION</head><p xml:id="_F7CU2ep"><s xml:id="_t4h6m3U">An estimated 537 million people, of which 44.7% undiagnosed, are nowadays living with diabetes mellitus worldwide.</s><s xml:id="_K9HSWAX">Type 2 Diabetes Mellitus (T2DM), formerly known as non-insulindependent or adult-onset diabetes, accounts for 90% of the population with diabetes <ref type="bibr" target="#b0">1</ref> .</s><s xml:id="_m98Atzh">Additional estimates indicate 541 million people having impaired glucose tolerance and 319 million having impaired fasting glucose levels, otherwise defined as prediabetes <ref type="bibr" target="#b0">1</ref> , and are as such at increased risk to progress to T2DM <ref type="bibr" target="#b1">2</ref> .</s></p><p xml:id="_6sxKVf4"><s xml:id="_hdNY2Tt">T2DM often occur together with hypertension <ref type="bibr" target="#b2">3</ref> , another major risk factor for cardiovascular disease.</s><s xml:id="_AKrkkMh">Regarding its prevalence, hypertension affects around 1.28 billion or onethird of all adults between 30 and 79 globally, with 46% of them being unaware of the condition (<ref type="url" target="https://www.who.int/news-room/fact-sheets/detail/hypertension">https://www.who.int/  news-room/fact-sheets/detail/hypertension</ref>).</s><s xml:id="_4K8XYD8">Prevalence is slightly decreasing in high-income countries but it is still on the rise in low-and middle-income countries <ref type="bibr" target="#b3">4</ref> .</s><s xml:id="_vQYndts">An additional quarter to half of the global adult population is presumed to have pre-hypertension, defined as high normal office systolic and diastolic BP <ref type="bibr" target="#b4">5</ref> .</s></p><p xml:id="_cfaH25g"><s xml:id="_m8Uwg6n">Both diabetes and hypertension impose a substantial burden on healthcare budgets with 11.5 and 10% of global health expenditures spent on diabetes <ref type="bibr" target="#b0">1</ref> and high BP <ref type="bibr" target="#b3">4</ref> , respectively.</s><s xml:id="_fwYRd9P">It is encouraging that preventive measures targeting modifiable lifestyle risk factors could result in substantial health and economic gains <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b5">6</ref> .</s><s xml:id="_t274euE">Lifestyle interventions focusing on diet modifications and increased physical activity have been proven effective in reducing HbA1c-levels and BP values <ref type="bibr" target="#b6">7</ref> , and despite some discrepant results and varying study quality, these lifestyle interventions were found to be cost-effective as well <ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref> .</s><s xml:id="_ZxnMhGG">Lifestyle interventions are thus valid strategies but the cost-effectiveness of various programmes and their drivers still need to be better documented.</s><s xml:id="_bdnMz6Q">Staff labour cost is such an important driver, accounting for the larger part of lifestyle intervention costs and could thus be a potential target for improving cost-effectiveness <ref type="bibr" target="#b10">11</ref> , for instance with the use of digital health interventions.</s></p><p xml:id="_BRawh5p"><s xml:id="_heAmAzC">There is increasing evidence of digital health interventions as a practical, low labour and low cost delivery mode <ref type="bibr" target="#b11">12</ref> that can foster clinical-effectiveness and cost-effectiveness of such lifestyle measures.</s><s xml:id="_ASwgz9W">The potential is great since 92% of the global population uses a mobile phone <ref type="bibr" target="#b12">13</ref> .</s><s xml:id="_n6CGDcD">The clinical effectiveness of digital health in diabetes and hypertension management has been confirmed <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> but limited cost-effectiveness data have been referred to as one of the major barriers for widespread implementation <ref type="bibr" target="#b20">21</ref> .</s><s xml:id="_zzCXkDq">Yet, Iribarren et al. <ref type="bibr" target="#b21">22</ref> reported that 75% of full economic studies (i.e., a comparison of both costs and health consequences of two or more alternatives) in a broad range of conditions found cost-effective or cost-saving results for mobile health solutions.</s><s xml:id="_dEZMh6U">Specifically, for T2DM, previous systematic reviews focused mainly on partial economic evaluations (i.e., single programme description of both costs and health consequences, or cost description/analysis of one or more alternatives) <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref> .</s><s xml:id="_aypDhjW">Nevertheless, the few full economic evaluations showed favourable results for digital health intervention modes such as phone/video calls, Short Message Service (SMS), and telemonitoring <ref type="bibr" target="#b22">23</ref> .</s></p><p xml:id="_4Bkp2gA"><s xml:id="_jkFwUzD">The current study aims to systematically review full health economic evaluations of digital health interventions targeting the prevention and treatment of T2DM and/or hypertension in adults with (pre)diabetes and/or (pre)hypertension: smartphone applications, text-messaging, and websites are the subject of investigation <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> .</s><s xml:id="_vmvrwYb">This systematic review extends previously published systematic reviews that were mainly based on partial economic evaluations.</s><s xml:id="_N3ByRpj">Although such evaluations can provide some trends in this field, it is critically important in rapidly evolving research fields, such as digital health, to synthesize and report on more comprehensive economic evaluations <ref type="bibr" target="#b24">25</ref> .</s><s xml:id="_57zu2Nq">The current systematic review focuses on three specific digital technology modes and discusses the health economic evidence for each mode separately.</s><s xml:id="_uVe47EM">Finally, this review puts emphasis on the methodological quality appraisal, with a focus on making informed recommendations to improve methodological quality.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8YhWNz6">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_pKq6rWh">Study selection</head><p xml:id="_dZcYB6z"><s xml:id="_fUqPFqK">The process of study identification, screening, and inclusion is displayed in the PRISMA flow diagram in Fig. <ref type="figure" target="#fig_0">1</ref>.</s><s xml:id="_xtE3nzC">From 3056 studies (2503 after duplicate removal) identified through database searches, 14 studies evaluated the value for money of either website <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref> , text-messaging <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref> , or smartphone application interventions <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref> .</s><s xml:id="_U6KJ9Vh">An overview of study characteristics, intervention details, and health economic outcomes can be found in Table <ref type="table" target="#tab_0">1</ref>.</s><s xml:id="_DSyrsPq">Supplementary note 1 shows excluded studies at full text screening with reasons.</s><s xml:id="_BCbc2Ps">Augustovski et al. <ref type="bibr" target="#b30">31</ref> and Zhang et al. <ref type="bibr" target="#b35">36</ref> reported on the same trial but the former was a trial-based analysis while the latter was model-based to extrapolate costs and effects on the long-term.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_SQCcXfz">Study characteristics</head><p xml:id="_hGjDnWN"><s xml:id="_VuWXs4Y">Included studies reflected a broad geographic distribution with one study conducted in North America <ref type="bibr" target="#b25">26</ref> , one in Central America <ref type="bibr" target="#b31">32</ref> , two in South America <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b35">36</ref> , four in East Asia <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref> , one in South Asia <ref type="bibr" target="#b32">33</ref> , two in the Middle East <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b34">35</ref> , and three in Europe <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> .</s></p><p xml:id="_7gxK33f"><s xml:id="_RKYvKNz">Eight studies included people with  Table 1 continued Study characteristics Intervention Health economic outcomes Study Country Patient population, sample size Design &amp; Time horizon Perspective Discount rate Digital health intervention In combination with other (digital) interventions?</s><s xml:id="_G5TeBFK">Comparator Incremental costs [converted to €, 2022] Incremental effects ICUR/ICER/ROI [converted to €, 2022] Authors' conclusion Derakhshandeh-Rishehri et al. (2022) Iran Non-insulin dependent T2DM IG: 35 CG: 35 CG2: 35 Trial-based Patient perspective reported but conflicts with cost overview / Web/online nutrition education once a month with internet and WhatsApp training upfront / CG1: monthly group sessions with similar education content as IG CG2: CAU (although CAU was nonexisting due to Covid-19) $, 2021: IG vs CG1: -21,853 [-€18,067] IG vs CG2: 4971 [-€4110] HbA1c: IG vs CG1: -0.17% IG vs CG2: -0.23% $/% HbA1c reduction: IG vs CG1: dominant IG vs CG2: 21,613 [-€17,869] Cost-effective compared to care as usual Faleh Al-Mutairi et al. (2021) Saudi Arabia T2DM IG: 100 CG: 100 Retro-spective matched cohort study 4 months Public healthcare system 1 / Text-messaging for education and medication management -Telemonitoring -Teleconsultation CAU (Inperson care, which requires physical attendance at the integrated care clinic) SAR,2020: 669 [€897] HbA1c: -0.28% SAR/% HbA1c reduction: 2373 [€1356] Cost-effective 3 Gilmer et al. (2019) Mexico T2DM IG: 102 CG1: 99 CG2: 99 Markov model Lifetime Public healthcare system 3% Text-messaging (and videos) -Telemonitoring -Teleconsultation -Self-management training -Education of physicians and nurses CAU+ -CG1: self-management training and education of physicians and nurses -CG2: monthly faceto-face followup and option to join a monthly peer support group $, 2017: IG vs CG1: 212 [€190] IG vs CG2: 599 [€537] QALY IG vs CG1: 0.05 IG vs CG2: 0.22 $/QALY IG vs CG1: 4299 [€3855] IG vs CG2: 2220 [€1991] Cost-effective Islam et al. (2020) Bangladesh T2DM IG: 118 CG: 118 Trial-based 6 months Limited public healthcare system / Text-messaging / CAU BDT, 2013: 558 [€21] QALY: 0.010 HbA1c: -0.64% BDT/QALY: 55,800 [€2077] BDT/% HbA1c reduction: 871 [€32] Cost-effective Table 1 continued Study characteristics Intervention Health economic outcomes Study Country Patient population, sample size Design &amp; Time horizon Perspective Discount rate Digital health intervention In combination with other (digital) interventions?</s><s xml:id="_HXMdgnB">Comparator Incremental costs [converted to €, 2022] Incremental effects ICUR/ICER/ROI [converted to €, 2022] Authors' conclusion Li et al. (2018) United Kingdom T2DM IG: 185 CG: 189 Trial-based 12 months Public healthcare system / -Web: education, social network support, and ask the expert facility.</s><s xml:id="_dqyy5n9">-Text-messaging / C A U + Access to comparator website containing basic information plus education on how to use the website.</s><s xml:id="_TQQFwYv">£, 2014: 111 [€149] QALY: 0.020 PAID: -1.9 £/QALY: 5550 [€7454] £/unit improvement on PAID scale: 58 [€78] Cost-effective Li et al. (2021) China T2DM IG: 130 CG: 85 Trial-based 12 months Public healthcare system 1 / Smartphone app to provide peer support, patient education, telemonitoring and communication with care provider / C A U + Three monthly examination of HbA1c, FBG, and P2BG levels to support medication adjustments.</s><s xml:id="_4ddz8mC">Patient education at each encounter.</s><s xml:id="_nHAeexE">CNY, 2019: 2 -606 [-€149] Prevalence difference in HbA1c control rate ( &lt; 7%): 27.50% CNY/patient with controlled HbA1c level: -2202 [-€540] Dominant McManus et al. (2021) United Kingdom Hypertension IG: 305 CG: 317 Trial-based 12 months Public healthcare system 1 / Web education -Telemonitoring -Education of healthcare workers -Up to 6 brief contacts to support behavioural changes CAU+ Online patient leaflet for hypertension.</s><s xml:id="_54X9Gxc">£, 2019: 2 38 [€47] QALY: 0.002 SBP: -3.5 mmHg £/QALY: not calculated as QALY difference was insignificant £/unit SBP reduction: 11 [€14] Cost-effective 3 Tsuji et al. (2020) Japan T2DM cohort Markov model 20 years Limited public healthcare system 4% Smartphone app for telemonitoring and communication with care provider and family.</s><s xml:id="_p45fY8M">/ C A U $, 2018: 2 3634 [€3187] QALY: 0.11 $/QALY: 33,039 [€28,971] Simulated result which should be confirmed by future trial data Cost-effective</s></p><p xml:id="_RJxgvTS"><s xml:id="_Fjbz4aQ">T2DM <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b38">39</ref> , two included people with prediabetes <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b33">34</ref> , and four studies focused on people with hypertension <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b37">38</ref> .</s></p><p xml:id="_nhxET22"><s xml:id="_vgamwae">Five studies were within-trial analyses with a time horizon between 6 and 18 months and a public healthcare system perspective <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b38">39</ref> , while one was a retrospective matched cohort study applying similar analytics <ref type="bibr" target="#b34">35</ref> .</s><s xml:id="_Q7Hq4YX">The within-trial analysis of Derakshandeh-Rishehri et al. <ref type="bibr" target="#b29">30</ref> applied a patient perspective but this is disputable.</s><s xml:id="_KNp2eck">One study used a decision tree-based model with a time horizon of 6 months and a patient perspective <ref type="bibr" target="#b37">38</ref> .</s><s xml:id="_9g4p9hJ">Five studies used a Markov model to estimate long-term (i.e., 10 years to lifetime) costs and effects based on clinical trial inputs, and whereby three applied a public healthcare system perspective <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b35">36</ref> and one a healthcare payer perspective <ref type="bibr" target="#b25">26</ref> .</s><s xml:id="_YVzxAT6">Finally, there was one Markov-model study which did not directly stem from one particular implementation study (i.e., all input parameters were literature driven) and which applied a 20-year horizon <ref type="bibr" target="#b36">37</ref> .</s><s xml:id="_sTemJhD">All studies with a time horizon of more than 1 year applied discount rates for both future costs and health outcomes between 3 and 5% <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b36">37</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2J8KRXv">Interventions</head><p xml:id="_paCVuDy"><s xml:id="_TYRyJR3">Four studies evaluated the use of smartphone applications, one in people with hypertension <ref type="bibr" target="#b37">38</ref> and three in people with T2DM <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b38">39</ref> .</s><s xml:id="_SpNw5Uw">Smartphone applications were used for monitoring, treatment adaptation, and communication between patients and healthcare professionals (in Tsuji et al. <ref type="bibr" target="#b36">37</ref> , also for communication with family).</s><s xml:id="_Tup5fmZ">The smartphone applications in Li et al. <ref type="bibr" target="#b38">39</ref> and Cunningham et al. <ref type="bibr" target="#b28">29</ref> were also used for patient education.</s><s xml:id="_vZrgwe2">The smartphone application in Zhang et al. <ref type="bibr" target="#b37">38</ref> included a health agenda (i.e., reminders for follow-up).</s><s xml:id="_sNfy4Qt">None of the four studies on smartphone applications included non-digital intervention features.</s></p><p xml:id="_j2vxJgm"><s xml:id="_RrhRm6U">Seven text-messaging <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref> and five website-based studies <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref> were included.</s><s xml:id="_K5XXSBH">One intervention combined textmessaging and websites <ref type="bibr" target="#b26">27</ref> , while five other interventions also comprised (non-)digital health modalities such as the implementation of a case manager or teleconsultation <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> .</s><s xml:id="_QCWpx2Q">Textmessaging was used to encourage the adoption of healthier lifestyle behaviours by participants.</s><s xml:id="_ARHyUY5">The length of the intervention ranged from 16 weeks to 2 years, and the frequency of text messages could be as high as daily but it was not always reported.</s><s xml:id="_mZRfkps">The website-based intervention component consisted of educational web pages and social network support groups, often in addition to teleconsultation, face-to-face follow-up, and/ or telemonitoring.</s></p><p xml:id="_FFH6P8v"><s xml:id="_ZFbwvQZ">Interventions were compared to care as usual <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref> or an enhanced version of care as usual (comprising selfmanagement training, education, and/or physician training) <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b38">39</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_fYqdevP">Health outcomes</head><p xml:id="_KmTk6Vg"><s xml:id="_8GV3xVU">Ten studies reported on the cost per quality adjusted life year (QALY) as the primary health economic outcome <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref> . Some studies</s><s xml:id="_yk8T457">reported clinical outcomes such as systolic blood pressure reduction <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b30">31</ref> , HbAc1 reduction <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35</ref> , proportion of population reaching hypertension <ref type="bibr" target="#b30">31</ref> or glycemic control <ref type="bibr" target="#b38">39</ref> , life years gained <ref type="bibr" target="#b33">34</ref> , and points gained on the problem areas in diabetes control (PAID) scale <ref type="bibr" target="#b26">27</ref> .</s><s xml:id="_fSczctM">The cost-minimisation study of Chen et al. <ref type="bibr" target="#b25">26</ref> reported on the return on investment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Hctwtxe">Quality appraisal</head><p xml:id="_UhaS9KV"><s xml:id="_gU7tKU8">Table <ref type="table">2</ref> shows the critical appraisal of selected studies for the evaluation of their quality.</s><s xml:id="_Q7eqft9">More than half of the included studies did not provide sufficient detail on the comparative alternatives (i.e., what does care as usual actually mean).</s><s xml:id="_zTc96su">Nine studies did not</s></p><p xml:id="_vNQE2EA"><s xml:id="_Tygsewx">Table 1 continued Study characteristics Intervention Health economic outcomes Study Country Patient population, sample size Design &amp; Time horizon Perspective Discount rate Digital health intervention In combination with other (digital) interventions?</s><s xml:id="_8hGHcKm">Comparator Incremental costs [converted to €, 2022] Incremental effects ICUR/ICER/ROI [converted to €, 2022] Authors' conclusion Wong et al. (2016) China Prediabetes IG:54 CG:50 Markov model Lifetime Public healthcare system 3% Text-messaging / CAU+ Information booklets on (pre)diabetes and health behaviour.</s><s xml:id="_mK5vrKU">$, 2011: -1020 [-€1006] QALY: 0.071 Life years: 0.063 $/QALY: -14,371 [-€14,177] $/Life year: -16,196 [-€15,977] Dominant Zhang et al. (2020) China Hypertension IG: 101 CG1: 95 CG2: 87 Decision tree model 6 months Patient / Smartphone app to provide patient education, guidance, telemonitoring, health agenda.</s><s xml:id="_fedKNXj">/ -CG1: CAU -CG2: CAU+ self-management CNY, 2017: IG vs CG1: 105 [€27] IG vs CG2: 590 [€150] CG2 vs CG1: -485 [-€124] QALY: IG vs CG1: 0.007 IG vs CG2: 0.002 CG2 vs CG1: 0.005 CNY/QALY IG vs CG1: 15,000 [€3825] IG vs CG2: 295,000 [€75,233] CG2 vs CG1: -97,000 [-€24,738] Cost-effective compared to CAU but not compared to CAU+ 1 perspective not reported but authors' judgement based on available information; 2 reference year not reported so publication year minus two; 3 no willingness-to-pay threshold reported or no valid argumentation given why the given willingness-to-pay threshold is justified; CAU care as usual, CG control group, ICER incremental cost-effectiveness ratio, ICUR incremental cost-utility ratio, IG intervention group.</s><s xml:id="_N3MycWT">QALY quality-adjusted life year, ROI return-on-investment.</s></p><p xml:id="_9q7EHhe"><s xml:id="_mn5MFQW">describe important costing aspects such as how the costs were measured or the sources of cost valuation <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref> . A rather sh</s><s xml:id="_4wHFYVH">rt time horizon was applied in more than half of the studies <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b38">39</ref> despite a long-time horizon being recommended in evaluating cost-effectiveness of chronic diseases to capture all relevant costs and effects.</s><s xml:id="_fkqkPfs">Moreover, all but one study <ref type="bibr" target="#b26">27</ref> did not provide sufficient argumentation for choosing another perspective to the societal one.</s><s xml:id="_t4tXHAq">Finally, only six studies reported both probabilistic sensitivity results plus another kind of sensitivity analysis such as threshold analysis or one-way sensitivity analysis on top of the point estimate results <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b35">36</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_J9mM4mW">Data synthesis</head><p xml:id="_zVscTTW"><s xml:id="_MP9k2Yf">Among the studies expressing results in QALYs, the ICURs varied between dominant (i.e., less costly and better health outcomes) and €75,233/QALY, with a median of €3840/QALY (interquartile range €16,179).</s><s xml:id="_mEQgSxc">One study did not find a QALY difference (Fig. <ref type="figure">2</ref>).</s><s xml:id="_JMn6jC7">None of the three digital health intervention modes was associated with substantially better cost-effectiveness results than the others.</s><s xml:id="_m8JfQ8K">Four out of fourteen studies (one on text messaging, two on mainly smartphone applications, and one on websitebased education) reported cost-saving results <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b38">39</ref> .</s><s xml:id="_85rxBMB">Smartphone applications were appraised by the studies' authors as cost-effective <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref> or dominant <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b38">39</ref> compared to usual care.</s><s xml:id="_kuxDYQ5">However, the cost-effective results in Tsuji et al. <ref type="bibr" target="#b36">37</ref> were associated with considerable uncertainty and should be confirmed by future trial data, as effectiveness data were simulated and the prediction model had been built on major assumptions.</s><s xml:id="_N3CSPRq">Li et al. <ref type="bibr" target="#b38">39</ref> did not report uncertainty analyses.</s><s xml:id="_r24cRYV">Furthermore, the smartphone application in Zhang et al. <ref type="bibr" target="#b37">38</ref> was reported as not cost-effective compared to a self-management intervention: QALY gain was higher but at a considerable cost: a self-management strategy appeared to be the preferred strategy from a health economic perspective (Fig. <ref type="figure">2</ref>).</s></p><p xml:id="_2CeuAmS"><s xml:id="_A4ACj6j">Text-messaging alone, or in combination with other intervention aspects (such as teleconsultation, telemonitoring, case management), was found to be cost-effective <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref> or even cost-saving <ref type="bibr" target="#b33">34</ref> . Altho</s><s xml:id="_Tf6gBDs">gh QALY gains were limited (ranging from a 0.01 increment per target person after 6 months in Islam et al. <ref type="bibr" target="#b32">33</ref> to a 0.22 increment per target person taking a lifetime horizon in Gilmer et al. <ref type="bibr" target="#b31">32</ref> ), the ICUR appeared to be robust in probabilistic sensitivity analysis <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b35">36</ref> .</s><s xml:id="_JffcFUH">This can be related to the low intervention costs since Islam et al. <ref type="bibr" target="#b32">33</ref> demonstrated that programme costs could at least be doubled while remaining cost-effective.</s><s xml:id="_VT2vnwx">Wong et al. <ref type="bibr" target="#b33">34</ref> even calculated that programme costs could be 50 times greater before the break-even point would be reached.</s><s xml:id="_SqrJWvU">Moreover, Li et al. <ref type="bibr" target="#b26">27</ref> argued that the health economic results of text-messaging can be even further improved by upscaling so that the cost per person decreases.</s><s xml:id="_k2EEvTx">Importantly, the ICUR in Gilmer et al. <ref type="bibr" target="#b31">32</ref> turned cost-effective only after 10-20 years, which was inconsistent with other studies that demonstrated costeffectiveness in the short term <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b32">33</ref> .</s></p><p xml:id="_MSjSs9u"><s xml:id="_nhR7sX7">Website-based interventions appeared to be costeffective <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b29">30</ref> , dominant <ref type="bibr" target="#b28">29</ref> , or cost-saving <ref type="bibr" target="#b25">26</ref> , even though only a natural effect (i.e., a reduction in systolic blood pressure; the incremental number of QALYs was not significant) was found in the study by McManus et al. <ref type="bibr" target="#b27">28</ref> .</s><s xml:id="_twqghvk">Yet scenario analysis, in which the</s></p><p xml:id="_GEVGTs6"><s xml:id="_td5KZWg">Table 2. Quality appraisal with the CHEC-list.</s></p><p xml:id="_KVwFWwf"><s xml:id="_SHp9HSz">Augustovski (2018) Zhang (2021) Chen (2016) Cunningham (2022) Derakhshandeh-Rishehri (2022) Faleh Al-Mutairi (2021) Gilmer (2019) Islam (2020) Li (2018) Li (2021) McManus (2021) Tsuji (2020) Wong (2016) Zhang (2020) Study population 0 0 1 1 1 1 0 1 1 1 1 1 1 1 79%</s></p><p xml:id="_sg4vjZa"><s xml:id="_TwRZaE5">Competing alternatives</s></p><formula xml:id="formula_0">0 0 0 0 0 1 1 0 1 1 1 0 0 1 43% Research question 0 0 0 1 1 0 0 0 1 1 1 0 0 0 36% Study design 1 1 0 1 0 1 1 1 1 1 1 1 1 1 86% Time horizon 0 1 1 1 0 0 1 0 0 0 0 1 1 0 43% Perspective 0 0 0 0 0 0 0 0 1 0 0 0 0 0 7% Costs: identification 1 1 1 1 0 1 1 0 1 1 0 0 1 1 71% Costs: measurement 1 1 0 0 0 0 1 0 1 0 0 1 1 1 50% Costs: value 1 1 0 0 0 0 1 0 1 0 0 1 1 0 43% Outcomes: identification 1 1 NA 1 1 1 1 1 1 1 1 1 1 1 100%</formula><p xml:id="_fKjmAYc"><s xml:id="_htG8b9S">Outcomes: measurement</s></p><formula xml:id="formula_1">1 1 NA 0 1 1 1 1 1 1 1 1 1 1 92%</formula><p xml:id="_Skra6Zs"><s xml:id="_BQaHYgG">Outcomes: value</s></p><formula xml:id="formula_2">1 1 NA 0 0 0 1 1 1 1 1 1 0 1 77% Incremental analysis 1 1 NA Sensitivity analysis 1 1 0 1 0 0 1 0 1 0 1 0 0 0 43% Conclusions 1 1 1 1 0 1 0 0 1 1 1 0 1 1 71% Generalizability 0 1 1 1 1 1 1 1 1 0 1 1 0 0 71% No conflict of interest 1 1 0 0 1 1 1 1 1 1 0 0 1 1 71% Ethics 1 1 0 1 0 0 0 1 1 0 1 0 0 1 50%</formula><p xml:id="_Q3qaEGw"><s xml:id="_pYg5MMG">Quality score (%) 68 79 40 63 42 56 74 50 94 61 67 58 63 67</s></p><p xml:id="_zaePT46"><s xml:id="_8UaYkvx">More extensive item assessment instructions can be found in Appendix 3. NA not applicable.</s></p><p xml:id="_TQXSmJR"><s xml:id="_ESCRD2v">intervention effect partly faded away, and probabilistic sensitivity analyses showed the results to be robust at given thresholds <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> .</s><s xml:id="_fz9ANda">Sensitivity and subgroup analyses were limited in most studies, which restricts the identification of cost-effectiveness drivers.</s><s xml:id="_3Xxb52X">First, Augustovski et al. <ref type="bibr" target="#b30">31</ref> reported on patient baseline characteristics: the intervention appeared to have greater value for money in populations of younger age, subjects with higher cardiovascular risk, higher body mass index, and women.</s><s xml:id="_Ar9ZFxf">The gender difference has been reported by Cunningham et al. <ref type="bibr" target="#b28">29</ref> as well.</s></p><p xml:id="_CxTdw3r"><s xml:id="_Yqs84rf">Secondly, intervention aspects influenced the ICER/ICUR as well.</s><s xml:id="_fPyqANn">A less intensive so less costly intervention following lower treatment adherence was reported by Augustovski et al. <ref type="bibr" target="#b30">31</ref> , thus being indicative of better cost-effectiveness although the observed differences were not statistically significant.</s><s xml:id="_26nA9c4">Meanwhile drop-out rates did not impact the ICER/ICUR in Wong et al. <ref type="bibr" target="#b33">34</ref> .</s><s xml:id="_Fvm9WBX">Costs were important drivers of cost-effectiveness in other studies as well <ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b37">38</ref> .</s></p><p xml:id="_e7yVUdp"><s xml:id="_4ufFjqC">Third, modelling assumptions was the third and most investigated pillar of what drives cost-effectiveness results.</s><s xml:id="_fXkkRsD">The value for money improved with longer time horizons <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b31">32</ref> , and the impact of transition probabilities, utility values, and discount rate on the ICUR were mixed <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref> .</s></p><p xml:id="_jM7tnUv"><s xml:id="_VkgbfRm">Whether digital health interventions targeting (pre)T2DM versus hypertension populations resulted in different cost-effectiveness outcomes, is difficult to assess because only three studies targeted populations with hypertension.</s><s xml:id="_KSBzqw4">However, it seems that digital health interventions targeting (pre)T2DM populations showed consistently positive cost-effective results <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b38">39</ref> , while cost-effectiveness results in hypertension populations were more mixed <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b37">38</ref> .</s></p><p xml:id="_w2XkSEp"><s xml:id="_3Wgp273">Whereas six studies evaluated one particular digital health mode, there were two studies that combined two of the digital health modes under investigation <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b28">29</ref> , two studies where the digital health mode was part of a broader digital intervention including telemonitoring <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b34">35</ref> , and four studies (three interventions) where the digital health mode was part of a broader health system intervention including digital and non-digital components <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b35">36</ref> .</s><s xml:id="_vbq2zTE">Website-interventions, text messaging, and smartphone applications were complemented by, or were seen as a complement of, other intervention components in four out of five, four out of six, and one out of four times, respectively.</s><s xml:id="_hfSvdW9">Gilmer et al. <ref type="bibr" target="#b31">32</ref> and Zhang et al. <ref type="bibr" target="#b35">36</ref> evaluated two of the broader health system interventions and found relatively higher health effects (0.22 and 0.13 QALYs, respectively) compared to stand-alone interventions.</s><s xml:id="_RYPz9y9">Note that these two studies applied a long-term perspective, contrary to McManus et al. <ref type="bibr" target="#b27">28</ref> who evaluated a broad health system intervention and who found only a systolic blood pressure reduction on the short-term but no QALY improvement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3bBKtqc">DISCUSSION</head><p xml:id="_dFgN8Jd"><s xml:id="_mNWY8CW">This review aimed to synthesize the available health economic evidence of digital health interventions in populations with or at risk of T2DM and/or hypertension.</s><s xml:id="_nju5YPW">Digital health interventions were restricted to smartphone applications, text-messaging, and website-based interventions.</s><s xml:id="_x3QA5xq">The three digital health intervention modes were found to be cost-effective or cost-saving compared to care as usual and, most of the time, to enhanced care as usual too.</s><s xml:id="_vjRTv4K">Median ICUR of cost-utility studies was low with €3840/QALY.</s></p><p xml:id="_4xgv8fV"><s xml:id="_dDesqPc">Recent meta-analyses from our team have shown the three digital health interventions to be equally effective in reducing BP in adults with hypertension, while text-messaging and smartphone application interventions were associated with increased improvements in glycaemic control compared to website-based interventions in adults with T2DM <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> .</s><s xml:id="_RCCy5hy">However, increased effects did not always offset additional costs: when comparing the three digital intervention modes with (enhanced) care as usual, our analysis did not show a strong preference in terms of costeffectiveness for one particular mode.</s></p><p xml:id="_wUfZVtV"><s xml:id="_zBRzqFe">Digital health interventions seem to be consistently costeffective in populations with (pre)T2DM but not in populations with hypertension.</s><s xml:id="_k6bCbYA">One possible explanation could be that the cost-effectiveness of implementing a digital health mode depends on the perceived severity of a condition and hence the urge to act upon.</s><s xml:id="_5ejxKdu">Hypertension is so widespread that some might perceive it merely as a risk factor instead of a disease <ref type="bibr" target="#b39">40</ref> , so patients and professionals could be less motivated to do something about it.</s><s xml:id="_3kP7yBd">For example, New Zealand does not have hypertension guidelines but bases its care recommendations on a cardiovascular risk score <ref type="bibr" target="#b40">41</ref> .</s><s xml:id="_jCBMSHP">Moreover, a global consensus definition of hypertension is lacking (see for example the definitions of different leading organisations: <ref type="url" target="https://tinyurl.com/whohyp">https://tinyurl.com/whohyp</ref>,</s><s xml:id="_2BmmHRG"><ref type="url" target="https://tinyurl.com/cdchyp">https://tinyurl.com/  cdchyp</ref>, <ref type="url" target="https://tinyurl.com/mayhyp">https://tinyurl.com/mayhyp</ref>,</s><s xml:id="_c5gqstf"><ref type="url" target="https://tinyurl.com/nhshypdef">https://tinyurl.com/  nhshypdef</ref>).</s><s xml:id="_FMaVntj">Smartphone applications, websites and textmessaging may have a significant clinical impact on BP, but there are possibly other approaches or other health objectives that better justify the money invested.</s><s xml:id="_MQzuxy4">This remains to be tested as the health economic evidence of smartphone apps, text-messaging, Fig. <ref type="figure">2</ref> Incremental cost-utility results (ICUR) estimates of included studies.</s><s xml:id="_c8UW4fV">Note that McManus et al. <ref type="bibr" target="#b27">28</ref> did not calculate an ICUR as QALY difference was insignificant.</s><s xml:id="_jNPSUwj">ICUR estimates in Cunningham et al. <ref type="bibr" target="#b28">29</ref> and Wong et al. <ref type="bibr" target="#b33">34</ref> were dominant.</s><s xml:id="_wRM7yqC">CG control group.</s><s xml:id="_5RGFtfa">*: asterisk denotes studies targeting populations with hypertension; studies without an asterisk include people with (pre)diabetes.</s><s xml:id="_mm7UBbU">Among other process evaluation constructs, adherence and reach are two important ones with a major impact on digital health interventions' cost-effectiveness <ref type="bibr" target="#b41">42</ref> .</s><s xml:id="_bjEega3">Patients who adhere with a smartphone application showed, for instance, better medication adherence <ref type="bibr" target="#b42">43</ref> .</s><s xml:id="_bWujfVd">However, high drop-out rates of 40% (95% CI 16-63%) in RCT's testing smartphone applications have been demonstrated as well <ref type="bibr" target="#b43">44</ref> .</s><s xml:id="_yyuRb4T">It has been suggested that attrition could, for instance, be reduced by using user feedback to enhance user experience, by enabling the possibility for users to contact health professionals (a so-called hybrid model), by focusing on self-management skills, by increasing health literacy, and by combining smartphone applications with internet or telehealth solutions <ref type="bibr" target="#b43">44</ref> .</s></p><p xml:id="_SRu3y6P"><s xml:id="_ue74b8v">Differentiating between primarily digital health interventions and primarily health system interventions with a digital component is warranted.</s><s xml:id="_gqEHdDY">Our results suggest that health system interventions might have the potential to gain more health effects on the long-term compared to a stand-alone digital health mode intervention, although current evidence is limited and mixed.</s><s xml:id="_bG3UZxv">However, Augustovski et al. <ref type="bibr" target="#b30">31</ref> suggested better costeffectiveness when the intervention was less intense.</s><s xml:id="_vZvjKpp">Although their statement should be interpreted cautiously because of overlapping confidence intervals between the different intervention intensities, these observations might be in line with the results of a meta-analysis on drop-out rates of exercise interventions that demonstrated a higher likelihood of drop-out in more intensive interventions <ref type="bibr" target="#b44">45</ref> .</s><s xml:id="_JTJ8cDv">Therefore, future interventions should carefully consider which features needs to be combined, knowing that more intervention features could improve effectiveness but a too intense intervention may also increase complexity of use thus having a detrimental impact on both drop-out and costeffectiveness.</s><s xml:id="_vTueQAC">Participant input via co-design may be of a help from the evidence gathering to the real-world testing stage <ref type="bibr" target="#b45">46</ref> .</s></p><p xml:id="_ZJ4veSs"><s xml:id="_ZQz3kF5">Given that there are hundreds of millions of people with or at risk of T2DM and hypertension, it is important to keep an eye on the scalability and budget impact of a new programme <ref type="bibr" target="#b41">42</ref> .</s><s xml:id="_rDueUbu">Whereas clinical effectiveness on the individual level can be optimised by adding possible intervention components to tailor care, less elaborated programmes may have a higher reach resulting in more population benefit within a closed budget.</s><s xml:id="_bQJ5UgJ">This could be of particular importance to digitally less-developed countries where digital interventions might be relatively more expensive.</s><s xml:id="_tcwRUx2">Scrutinizing the optimal intervention dose in different health systems including digitally less-developed countries is therefore paramount.</s><s xml:id="_pyQehhJ">Our results indicate for instance that text-messaging is appraised as cost-effective across studies, either in combination with other intervention features or not.</s><s xml:id="_ZbcrDXZ">Self-monitoring can also be a very powerful strategy to improve cost-effectiveness as well.</s><s xml:id="_PCpD3ES">It might therefore be an option to integrate such functionalities in smartphone applications.</s></p><p xml:id="_d3FaWvu"><s xml:id="_n7VY58K">Our quality appraisal demonstrated important methodological shortcomings.</s><s xml:id="_a8A2F8d">Based on these, our four key lessons for future health economic evaluations of digital health interventions are:</s></p><p xml:id="_ZWseFCj"><s xml:id="_fUH3PbJ">1. Health economic results can only be appraised correctly with an elaborate research question and sufficient context.</s><s xml:id="_jVy7u7a">The competing alternatives under investigationcare as usual in particularshould be detailed.</s><s xml:id="_tVWAvsF">The study's perspective should be justified and the applied time horizon should capture relevant long-term costs and effects of preventive measures <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b10">11</ref> .</s><s xml:id="_qpEHxyG">In this regard, it is important to stress the cost-effectiveness results of digital therapeutics despite the sometimes quite short time horizons applied.</s><s xml:id="_eR8h2ty">2. Transparency is pivotal when reporting applied costs: which costs have been included exactly (which refers to the perspective) and how these were measured and valued should be stated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3." xml:id="_7GRq9PQ">Health economic evaluations of digital health interventions</head><p xml:id="_VYvawQR"><s xml:id="_sceqR6F">often come with data uncertainty and assumptions.</s><s xml:id="_sJYYeuB">Oneway and probabilistic sensitivity analyses are at least needed to address these uncertainties, preferably in different subgroups.</s><s xml:id="_etzrt72">Following key lesson 1 on applying an appropriate long time horizon, it is pivotal to scrutinize the impact of the intervention effect's sustainability on the health economic outcome, especially given the high attrition and dropout rates in for instance app-based interventions <ref type="bibr" target="#b43">44</ref> .</s><s xml:id="_awQDejA">4. An ICUR does not have an intrinsic value and should always be evaluated in light of a willingness-to-pay threshold.</s><s xml:id="_8WgXmf2">Most included studies applied a threshold value of one to three times the gross domestic product (GDP) per capita, as recommended by the World Health Organisation <ref type="bibr" target="#b46">47,</ref><ref type="bibr" target="#b47">48</ref> , but critics argued that a more conservative threshold of ±50% the GDP per capita would better capture opportunity costs <ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b48">49</ref> .</s><s xml:id="_AdCqPr2">Note that, given such a conservative threshold, most cost-effectiveness estimates of digital health interventions remain cost-effective.</s><s xml:id="_evTpc7F">Furthermore, some studies applied natural units (e.g., cost per percentage HbA1c reduction).</s><s xml:id="_tuF8r7W">For instance, Derakhshandeh-Rishehr et al. <ref type="bibr" target="#b29">30</ref> , Faleh Al-Mutairi et al. <ref type="bibr" target="#b34">35</ref> and McManus et al. <ref type="bibr" target="#b27">28</ref> reported an increase in health effect at an increased cost and stated the result was cost-effective although no willingness-to-pay threshold or valid argumentation for the applied willingness-to-pay threshold was reported, respectively.</s></p><p xml:id="_tWUvH2f"><s xml:id="_VqywDDH">These key lessons should be considered in future research.</s><s xml:id="_bzqXwrd">Such studies should also strive to address evidence gaps in the field.</s><s xml:id="_rPJVVSA">Head-to-head studies are definitely needed to determine the digital health mode with the best value for money in different subgroups operating within a particular health system.</s><s xml:id="_rMVXwjb">The uncertainty associated with long-term health economic evaluations can be reduced by designing trials with longer clinical follow-up periods so the sustainability of the intervention effect can be modelled more precisely.</s><s xml:id="_m7Pb56g">Moreover, budget impact estimates are truly relevant for policy makers given the high prevalence of T2DM and hypertension, while uptake and attrition rates should also be taken into consideration as they can also have a significant effect on the costs.</s></p><p xml:id="_VAffa6Q"><s xml:id="_AY84ADm">The most important strengths of this review are the complementarity with previously published meta-analyses <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref> scrutinizing the effectiveness of the three digital health intervention modes, and the thorough quality appraisal resulting in several key lessons for health economic research.</s></p><p xml:id="_YHekPMP"><s xml:id="_9quKvQB">However, this systematic review also has limitations.</s><s xml:id="_WPDf28T">First, the adult filter is not consistent between the five searched databases.</s><s xml:id="_UnS3NNA">In Medline, the adult filter is &gt;19 years of age, whereas for EMBASE and PsycINFO it is &gt;18.</s><s xml:id="_TUBJ3Ys">However, the proportion of the population with T2DM or hypertension at that age is small <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b50">51</ref> .</s><s xml:id="_JK6BpG7">Second, studies on people with or at risk of T2DM or hypertension were included but the small number of studies impeded appropriate subgroup analyses.</s><s xml:id="_kHKv2N8">What may work in one population may not work in another.</s><s xml:id="_kHeWDyd">Third, only English articles were included and this may limit our conclusions, especially since T2DM and hypertension prevalence are high in large non-English-speaking countries such as India <ref type="bibr" target="#b51">52</ref> and China <ref type="bibr" target="#b52">53</ref> .</s><s xml:id="_FM5M4MM">However, included studies from the Americas, Europe, Asia, and the Middle-East reflected a geographically and demographically diverse population.</s><s xml:id="_XHkxpFE">Fourth, digital health solutions in five website-based or text-messaging studies have been augmented with other intervention features such as healthcare professional education, telemonitoring and/or (tele) consultations.</s><s xml:id="_TwUXThg">It is therefore not clear whether the intervention effect arises due to these additional intervention features or due to the digital intervention component.</s><s xml:id="_5R65AwA">Fifth, the number of full health economic papers remain scarce, especially compared to the accumulating amount of clinical effectiveness evidence, and the results of Tsuji et al. <ref type="bibr" target="#b36">37</ref> are based on disputable assumptions.</s><s xml:id="_vYyUSUm">Because of the low number of included papers, additional analyses of the impact of study quality on results were not conducted.</s><s xml:id="_TWBkzVD">Sixth, no head-to-head health economic studies of the three digital intervention modes were found.</s><s xml:id="_xUhmFJn">Seventh, health economic studies might be subject to multiple sources of publication bias including a publication bias in first health outcome publications and next economic publications.</s><s xml:id="_twYFJ4U">Funnel plotting to investigate possible publication bias was not an option in this study but Moschonis et al. <ref type="bibr" target="#b18">19</ref> and Siopis et al. <ref type="bibr" target="#b19">20</ref> demonstrated respectively a small and non-existing publication bias in our health outcome reviews.</s><s xml:id="_p8KVNdp">It is of course still possible that a publication bias favoring cost-effective or cost-saving results remains in economic publications, especially given the suboptimal reporting of sensitivity analyses <ref type="bibr" target="#b53">54</ref> .</s></p><p xml:id="_tcvvUNc"><s xml:id="_s8cPgmP">In conclusion, health economic evidence suggests that smartphone application, text-messaging, and website-based interventions are cost-effective and, in some cases, even cost-saving.</s><s xml:id="_QaAEdqh">It shows how challenging, but at the same time how possible, it can be to improve the health of the population while saving money.</s></p><p xml:id="_FGkUY9T"><s xml:id="_4tGMFqn">While previous research demonstrated that the three digital health intervention modes were equally clinically-effective in adults with hypertension, and that text-messaging and smartphone application interventions worked significantly better than website-based interventions in adults with T2DM, no costeffectiveness evidence was found supporting one particular digital health intervention mode over another.</s><s xml:id="_3y8vaMp">Moreover, textmessaging, smartphone application, and website-based interventions appeared to be consistently cost-effective in populations with (pre)T2DM, but not in populations with hypertension.</s></p><p xml:id="_dbRsAkg"><s xml:id="_skuNxsY">Based on the available evidence, policy makers and clinicians should make decisions on the most appropriate digital health interventions based on available budgets and well-defined health objectives.</s><s xml:id="_QaSCajt">The high penetration rate of digital applications in diverse populations is a strength but it is pivotal to keep process evaluation constructs in mind.</s><s xml:id="_R6fhwU7">Key lessons for future health economic studies on how to design studies and report on the results are given.</s><s xml:id="_y5TBZTz">It is important to pay special focus on the context, report the costs included and how these were measured and valued, conduct sufficient sensitivity analyses, and appraise the cost-effectiveness result more critically in light of a reasoned willingness-to-pay threshold.</s><s xml:id="_uACexBy">Head-to-head studies are missing while this would enhance understanding and practice substantially.</s><s xml:id="_2QRD7jJ">It is strongly recommended to consistently include a costeffectiveness work package alongside clinical trials <ref type="bibr" target="#b54">55</ref> .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sZTVBgr">METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3SbhAuy">Literature search</head><p xml:id="_xyAF8Kz"><s xml:id="_fDAZu92">The protocol (PROSPERO CRD42021247845) and reporting of this systematic review were consistent with the 2020 PRISMA guidelines <ref type="bibr" target="#b55">56</ref> .</s><s xml:id="_xGdgjRm">Five electronic databases (Medline via Ovid, Embase via embase.org,</s><s xml:id="_rakA5bD">CENTRAL via cochranelibrary.com,</s><s xml:id="_hgzrRbH">CINAHL via EBSCO, and APA PsycInfo via Proquest) were systematically searched for scientific publications on September 2, 2022.</s><s xml:id="_WTAm5mc">The applied search strategy consisted of population-related and intervention-related keywords, developed by Moschonis et al. <ref type="bibr" target="#b18">19</ref> and Siopis et al. <ref type="bibr" target="#b19">20</ref> , combined with a search string to detect economic evaluations, developed by Werbrouck et al. <ref type="bibr" target="#b56">57</ref> .</s><s xml:id="_NR2rrPj">The latter was originally based on previously published search strings.</s><s xml:id="_QANCjTg">References <ref type="bibr" target="#b57">58,</ref><ref type="bibr" target="#b58">59</ref> , but was broadened to maximize sensitivity <ref type="bibr" target="#b56">57</ref> .</s><s xml:id="_arKuAxw">The search strategy is further completely consistent with Moschonis et al. <ref type="bibr" target="#b18">19</ref> and Siopis et al. <ref type="bibr" target="#b19">20</ref> the literature search was restricted by age (adults only), publication date (1 January 2009 onwards to include contemporary evidence only), and language (English), if the search engine allowed to do so.</s><s xml:id="_nfN6eQ5">The search strategies for CENTRAL and CINAHL were further restricted to trials only and peer-reviewed manuscripts, respectively.</s><s xml:id="_3fET69g">The final search string can be found in Supplementary Methods 1.</s><s xml:id="_tM9BVdg">The search terms and inclusion criteria targeted a broad spectrum of studies with digital components to maximize detection rate.</s><s xml:id="_pmQrWpU">However, only studies with at minimum a smartphone application, text-messaging, or website-based intervention were eventually withheld.</s><s xml:id="_AUax3xU">Backward and forward citation tracking were performed to identify any studies missed by the search strategy.</s></p><p xml:id="_aBsUauV"><s xml:id="_SKce683">As this study is a systematic review, ethical approval was not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dNCRcR8">Study selection and data extraction</head><p xml:id="_mbsU3d2"><s xml:id="_cqNkQWs">Titles and abstracts were screened with Rayyan 60 by two independent reviewers (RW and NV) based on a priori developed eligibility criteria (Table <ref type="table" target="#tab_6">3</ref>).</s><s xml:id="_WgHBu8u">Importantly, not only head-to-head studies directly comparing the three digital health modes were included, but studies comparing the intervention including a digital health mode to usual care were included as well.</s><s xml:id="_qKJuZhr">Discrepancies were discussed between the two reviewers until consensus was reached.</s><s xml:id="_UNt6Gv4">A third reviewer (LA) was available but did not have to step in as there were no discrepancies left.</s></p><p xml:id="_6V5ceVP"><s xml:id="_gt5ecq8">Eligible full texts were screened by the first author (RW) and one-third of these full texts were screened by a second author (NV).</s><s xml:id="_t6R5yqU">Reference lists from articles that fitted the inclusion criteria were checked for missed articles.</s><s xml:id="_CEcfaAV">The following predetermined data were extracted from all included articles:</s></p><p xml:id="_pMJyyvw"><s xml:id="_EBR5JUb">• General study characteristics: publication year, country, participant characteristics, intervention alternatives;</s></p><p xml:id="_DCCzWp2"><s xml:id="_gT9Svkf">• Methods: study perspective (i.e., point of view), economic evaluation type, analytic approach, time horizon (i.e., period of analysis), discount rate (i.e., to convert a value received in the future to a value today), reference year of costs, willingness-topay threshold (i.e., what is society prepared to pay for health), intervention costs, health resource use and data sources, information regarding the base case and sensitivity analyses;</s></p><p xml:id="_w7zAbhN"><s xml:id="_SXUftS5">• Results and conclusion: (incremental) costs and effects, results from sensitivity analyses, author's conclusions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RjN2bD4">Quality appraisal</head><p xml:id="_vJeKXD8"><s xml:id="_mfABb8r">As recommended by van Mastrigt et al. <ref type="bibr" target="#b60">61</ref> , study quality has been appraised with the Consensus on Health Economic Criteria (CHEC) list <ref type="bibr" target="#b61">62</ref> , since this checklist enables the assessment of both trial-and model-based economic evaluations <ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b60">61</ref> .</s><s xml:id="_AqCxzHb">The two independent reviewers (RW and NV) followed Werbrouck et al. <ref type="bibr" target="#b56">57</ref> , who suggested small adaptions to the checklist (e.g., 'not applicable' was a valid answer option next to yes or no: for instance, whether or not discounting (item 14) was applied, was only considered applicable if a study's time horizon was &gt;1 year.</s><s xml:id="_2UgdQPG">Such adaptions resulted in a more valid appraisal of individual studies' quality) <ref type="bibr" target="#b56">57</ref> .</s><s xml:id="_HzP2U9J">Discrepancies were discussed by the two reviewers until consensus was reached by specifying assessment criteria.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_g4G2ueK">Evidence table and analysis</head><p xml:id="_bKMnNVw"><s xml:id="_zxmqJrh">The evidence table summarises study characteristics, treatment alternatives, and results from the incremental base case analyses.</s><s xml:id="_tdRCEmF">Sensitivity analyses are addressed in text.</s><s xml:id="_sJEJayJ">The following methodology applies:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_C38JrfB">•</head><p xml:id="_X49QZCu"><s xml:id="_AhnsrUK">The treatment in the comparator group has been dichotomised into care as usual (CAU) and enhanced care as usual (CAU + ).</s><s xml:id="_gkpBaJh">In the case of the latter, further description was provided.</s></p><p xml:id="_QpKYyxq"><s xml:id="_95JakJh">• Perspective could either be (i) the public healthcare system perspective (i.e., the third-party payer perspective), (ii) the healthcare payer perspective (i.e., including patient costs next to third-party payer costs), (iii) the societal perspective (i.e.</s><s xml:id="_Ea4Ye7Q">including the payer perspective and costs from productivity losses), (iv) the patient perspective, or (v) the organisational perspective.</s><s xml:id="_HesQVW9">In the case that the perspective was not explicitly stated, the authors made a judgement.</s><s xml:id="_MYBuDeK">A perspective could also be called 'limited': a limited societal perspective may for instance account for non-medical costs (i.e., costs such as transport costs to the hospital, which are costs outside the healthcare sector, but directly relatable to the disease) but not for indirect nonmedical costs (i.e., productivity losses due to absenteeism or presenteeism).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_S7euTwT">•</head><p xml:id="_7TfJkUw"><s xml:id="_nt7Teru">In order to improve the comparability between studies from different countries and different reference years <ref type="bibr" target="#b60">61</ref> , costs and incremental cost-effectiveness ratios (ICERs)/incremental costutility ratios (ICURs) were converted via an online calculator (<ref type="url" target="https://eppi.ioe.ac.uk/costconversion/">https://eppi.ioe.ac.uk/costconversion/</ref>) to 2022 Euro currency values with Belgium as the reference country, to account for purchasing power parities.</s></p><p xml:id="_TP57gZ9"><s xml:id="_Zht3nyR">Results were analysed together and per delivery mode, disease, and outcome measure.</s><s xml:id="_muF6HwC">Moreover, possible cost-effectiveness drivers were explored.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p xml:id="_7XTRvUH"><s xml:id="_NFvwZnV">Fig. 1 PRISMA flow diagram.</s></p></div></figDesc><graphic coords="2,140.37,59.30,324.00,316.57" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><figDesc><div><p xml:id="_sabtKEc"><s xml:id="_3vnRVZX">and website-based interventions in populations with hypertension remains very limited.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><graphic coords="8,140.37,516.47,324.00,185.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_6mB66Vw"><s xml:id="_QqJ5wSh">Evidence table.</s></p></div></figDesc><table><row><cell></cell><cell>Authors'</cell><cell>conclusion</cell><cell></cell><cell></cell><cell>Cost-</cell><cell>effective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Cost-</cell><cell>effective</cell><cell></cell><cell>Cost-</cell><cell>saving</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Dominant</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>ICUR/ICER/ROI</cell><cell>[converted to</cell><cell>€, 2022]</cell><cell></cell><cell>$/QALY: 3299</cell><cell>[€2958]</cell><cell>$/mmHG SBP</cell><cell>reduction:</cell><cell>26.43 [€23.70]</cell><cell>$/extra</cell><cell>person under</cell><cell>threshold: 721</cell><cell>[€646]</cell><cell>$/QALY: 4907</cell><cell>[€4400]</cell><cell></cell><cell>ROI at 3 y:</cell><cell>1.61</cell><cell>ROI at 5 y:</cell><cell>3.56</cell><cell>ROI at 10 y:</cell><cell>11.18</cell><cell></cell><cell></cell><cell></cell><cell>£/QALY: -1569</cell><cell>[-€1974]</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Health economic outcomes</cell><cell>Incremental Incremental</cell><cell>costs effects</cell><cell>[converted</cell><cell>to €, 2022]</cell><cell>$, 2017: 140 QALY: 0.042</cell><cell>[€126] SBP: -5.30</cell><cell>mmHG</cell><cell>Hypertension</cell><cell>control: 19%</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>$, 2017: 623 QALY: 0.13</cell><cell>[€559]</cell><cell></cell><cell>$, 2015 at /</cell><cell>3 y: -800</cell><cell>[-€739]</cell><cell>$, 2015 at</cell><cell>5 y: -3330</cell><cell>[-€3076]</cell><cell>$, 2015 at</cell><cell>10 y: -13,240</cell><cell>[-€12,230]</cell><cell>£, 2018: QALY: 0.054</cell><cell>-84.71</cell><cell>[-€106.57]</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Comparator</cell><cell></cell><cell></cell><cell></cell><cell>CAU</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>CAU</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>C A U</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Intervention</cell><cell>Perspective Discount rate Digital health In combination</cell><cell>intervention with other</cell><cell>(digital)</cell><cell>interventions?</cell><cell>Public 5% Text-messaging -Case manager</cell><cell>healthcare -Physician</cell><cell>system education</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Healthcare 3% Website-based -</cell><cell>payer intervention Telemonitoring</cell><cell>including a -Health coach</cell><cell>16 week online -24/7</cell><cell>training telephone and</cell><cell>programme and online</cell><cell>online social professional</cell><cell>network support availability</cell><cell>communities</cell><cell>Public 3.5% Website and /</cell><cell>healthcare smartphone app</cell><cell>system 1 for education</cell><cell>and access to</cell><cell>electronic</cell><cell>personal health</cell><cell>record for</cell><cell>communication</cell><cell>with</cell><cell>professionals,</cell><cell>patient</cell><cell>involvement,</cell><cell>and shared-</cell><cell>decision</cell><cell>making.</cell></row><row><cell></cell><cell>Design</cell><cell>&amp;</cell><cell>Time</cell><cell>horizon</cell><cell>Trial-</cell><cell>based</cell><cell>18</cell><cell>months</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Markov-</cell><cell>model</cell><cell>Lifetime</cell><cell>Markov</cell><cell>model</cell><cell>10 years</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Markov</cell><cell>model</cell><cell>10 years</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Study characteristics</cell><cell>Country Patient</cell><cell>population,</cell><cell>sample size</cell><cell></cell><cell>Argentina Hypertension</cell><cell>IG: 743</cell><cell>CG: 689</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>USA Prediabetes</cell><cell>IG: 997</cell><cell>CG: 1:1</cell><cell>match with</cell><cell>historical</cell><cell>cohort</cell><cell></cell><cell></cell><cell></cell><cell>United T2DM</cell><cell>Kingdom IG: 2576</cell><cell>CG: 5:1</cell><cell>match</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Study</cell><cell></cell><cell></cell><cell></cell><cell>Augustovski et</cell><cell>al. (2018)</cell><cell>and Zhang et</cell><cell>al. (2021)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Chen et</cell><cell>al. (2016)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Cunningham et</cell><cell>al. (2022)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 3 .</head><label>3</label><figDesc><div><p><s xml:id="_TFyymRv">Eligibility criteria.PopulationAdults with or at risk of T2DM and/or hypertension Children, adolescents, mixed patient populations without stratified results.Intervention Smartphone applications, text-messaging, or website interventionsOther digital health interventions (e.g.</s><s xml:id="_5VBC2uY">teleconsultation only, telemonitoring without the use of a smartphone app).</s></p></div></figDesc><table><row><cell></cell><cell>Inclusion criteria</cell><cell>Exclusion criteria</cell></row><row><cell>Comparator</cell><cell>Care as usual, face-to-face intervention etc.</cell><cell>N.A.</cell></row><row><cell>Outcomes</cell><cell>Full economic outcomes (e.g. cost-effectiveness; cost-utility</cell><cell>Outcomes related to either effectiveness, intervention</cell></row><row><cell></cell><cell>analysis) or studies capturing both intervention and health</cell><cell>costs, or health resource use costs only.</cell></row><row><cell></cell><cell>resource use costs (cost minimisation).</cell><cell></cell></row><row><cell>Publication type and</cell><cell>Original research: model-based or within-trial health economic</cell><cell>Pre/post, reports, systematic reviews, meta-analyses,</cell></row><row><cell>study design</cell><cell>evaluations</cell><cell>congress abstracts, protocols, commentaries, animal</cell></row><row><cell></cell><cell></cell><cell>studies</cell></row><row><cell>Language</cell><cell>English</cell><cell>Other languages</cell></row><row><cell>Published date</cell><cell>2009 to present</cell><cell>Before 2009</cell></row><row><cell cols="2">N.A. not applicable, T2DM type 2 diabetes mellitus.</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_HRPVwtA"><s xml:id="_ZUqwtVB">npj Digital Medicine (2023) 150 Published in partnership with Seoul National University Bundang Hospital 1234567890():,;</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_CSmWRzG"><s xml:id="_ex9QDX5">Published in partnership with Seoul National University Bundang Hospital npj Digital Medicine (2023) 150</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_eByTK6X"><s xml:id="_suKgjjA">npj Digital Medicine (2023) 150Published in partnership with Seoul National University Bundang Hospital</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_FaaDn4Z">ACKNOWLEDGEMENTS</head><p xml:id="_qrJZ5E7"><s xml:id="_2GhmaD9">The <rs type="projectName">DigiCare4You study</rs> has received funding from the <rs type="funder">European Union</rs>'s <rs type="programName">Horizon 2020 research and innovation programme</rs> under grant agreement <rs type="grantNumber">N°945246</rs>.</s><s xml:id="_VkSVFSk">G.S., G.M., D.K. and B.O. received funding from the <rs type="funder">National Health and Medical Research Council (NHMRC) of Australia</rs>, as part of the <rs type="funder">NHMRC European Union</rs> <rs type="programName">Collaborative Research Grant Scheme</rs>, under the agreement with the <rs type="grantNumber">NHMRC ID APP2007006</rs>.</s><s xml:id="_Jr268nE">R.V. declares receipt by <rs type="funder">New York University Grossman School of Medicine</rs> of a DigiCare4You funding subaward.</s><s xml:id="_WCR4mKc">The content of this article reflects only the authors' views, and the <rs type="institution">European Union</rs> is not liable for any use that may be made of the information contained therein.</s><s xml:id="_T9pSQaF">The funding source had no role in the study design, data collection, data analysis, data interpretation, writing of the manuscript, or in the decision to submit for publication.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funded-project" xml:id="_pUcxtWs">
					<idno type="grant-number">N°945246</idno>
					<orgName type="project" subtype="full">DigiCare4You study</orgName>
					<orgName type="program" subtype="full">Horizon 2020 research and innovation programme</orgName>
				</org>
				<org type="funding" xml:id="_TKc3ynq">
					<idno type="grant-number">NHMRC ID APP2007006</idno>
					<orgName type="program" subtype="full">Collaborative Research Grant Scheme</orgName>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_AjSN7B3">DATA AVAILABILITY</head><p xml:id="_n2fHg2T"><s xml:id="_QwQwWNz">Template data collection form and full data extracted from included studies will be made publicly available on The Open Science Framework under 'DigiCare4You health economics'.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4aNQUSD">Reporting summary</head><p xml:id="_vREphSH"><s xml:id="_CgFAc33">Further information on research design is available in the Nature Research Reporting Summary linked to this article.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_29NWRuw">AUTHOR CONTRIBUTIONS</head><p xml:id="_DMtXNHk"><s xml:id="_6q2WYEP">Conceptualisation: R.W., N.V., Y.M., L.A.; methodology: R.W., N.V., L.A.; data collection: R.W., N.V.; data analysis: R.W., N.V., L.A.; writing-original draft preparation: R.W.; writing-review and editing: all authors; supervision: L.A., G.M.; project administration: R.W., G.S.; funding acquisition: R.W., G.M., L.A., B.O., Y.M.</s><s xml:id="_KRXCFpf">All authors have read and agreed to the final version of the manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KbxCfem">COMPETING INTERESTS</head><p xml:id="_2TdqKEq"><s xml:id="_c95bGzK">L.A. received consulting fees from Mundipharma for advice on cost-effectiveness of SGLT2 inhibitors for the management of type 2 diabetes; honoraria from Boehringer Ingelheim and Mundipharma for lectures on health economic aspects of diabetes; is a member of the board of the AstraZeneca Foundation.</s><s xml:id="_47h2jjA">C.d.A. and S.G. are employees of the company Meteda, manufacturer of MetaClinic, DiaWatch METEDA, MetaDieta and MyDiet.</s><s xml:id="_PfQVVk6">All other authors declare no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_52gFtKG">ADDITIONAL INFORMATION Supplementary information</head><p xml:id="_cTVtRCQ"><s xml:id="_uaBW96J">The online version contains supplementary material available at <ref type="url" target="https://doi.org/10.1038/s41746-023-00876-x">https://doi.org/10.1038/s41746-023-00876-x</ref>.</s></p><p xml:id="_pd646Ej"><s xml:id="_NjJn8HG">Correspondence requests for materials should be addressed to Ruben Willems.</s></p><p xml:id="_rNgkAaj"><s xml:id="_mvg8qpm">Reprints and permission information is available at <ref type="url" target="http://www.nature.com/reprints">http://www.nature.com/  reprints</ref> Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<author>
			<orgName type="collaboration">IDF</orgName>
		</author>
		<idno type="DOI">10.1163/1570-6664_iyb_sim_org_38965</idno>
		<title level="m" xml:id="_cAqEwhR">IDF Atlas 10th edn</title>
		<imprint>
			<publisher>International Diabetes Federation</publisher>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">IDF. IDF Atlas 10th edn (International Diabetes Federation, 2021).</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_gwCrB2t">Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Morris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WReFPh9">Diabetologia</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1489" to="1493" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Morris, D. H. et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia 56, 1489-1493 (2013).</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_tnwtz7t">Diabetes, hypertension, and cardiovascular disease: an update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Sowers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Epstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Frohlich</surname></persName>
		</author>
		<idno type="DOI">10.1161/01.hyp.37.4.1053</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_44ykpRx">Hypertension</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="1053" to="1059" />
			<date type="published" when="1979">1979. 2001</date>
			<pubPlace>Dallas, Tex.</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Sowers, J. R., Epstein, M. &amp; Frohlich, E. D. Diabetes, hypertension, and cardio- vascular disease: an update. Hypertension (Dallas, Tex. : 1979) 37, 1053-1059 (2001).</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_7hxsAhV">The global epidemiology of hypertension</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stefanescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Vcn2Cw4">Nat. Rev. Nephrol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="223" to="237" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mills, K. T., Stefanescu, A. &amp; He, J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 16, 223-237 (2020).</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_H7TvMmW">Prehypertension-prevalence, health risks, and management strategies</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Egan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stevens-Fabry</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrcardio.2015.17</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2s8s257">Nat. Rev. Cardiol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="289" to="300" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Egan, B. M. &amp; Stevens-Fabry, S. Prehypertension-prevalence, health risks, and management strategies. Nat. Rev. Cardiol. 12, 289-300 (2015).</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_XWWVXvW">European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease Prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Piepoli</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12529-016-9583-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CXxJhRS">Eur. Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2315" to="2381" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease pre- vention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease Prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardi- ovascular Prevention &amp; Rehabilitation (EACPR). Eur. Heart J. 37, 2315-2381 (2016).</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_xJDqfq4">Efficacy of lifestyle interventions in patients with type 2 diabetes: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">L</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejim.2015.11.016</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9GTNA3G">Eur. J. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="37" to="47" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Huang, X. L. et al. Efficacy of lifestyle interventions in patients with type 2 dia- betes: a systematic review and meta-analysis. Eur. J. Intern. Med. 27, 37-47 (2016).</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_3svpcb3">Lifestyle interventions to prevent type 2 diabetes: a systematic review of economic evaluation studies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Alouki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Delisle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bermúdez-Tamayo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Johri</surname></persName>
		</author>
		<idno type="DOI">10.1155/2016/2159890</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cU86Tpj">J. Diabetes Res</title>
		<imprint>
			<biblScope unit="page">2159890</biblScope>
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Alouki, K., Delisle, H., Bermúdez-Tamayo, C. &amp; Johri, M. Lifestyle interventions to prevent type 2 diabetes: a systematic review of economic evaluation studies. J. Diabetes Res. 2016, 2159890 (2016).</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_3HajDAT">Preventing type 2 diabetes: systematic review of studies of costeffectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZKKt5a9">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">17184</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Roberts, S. et al. Preventing type 2 diabetes: systematic review of studies of cost- effectiveness of lifestyle programmes and metformin, with and without screen- ing, for pre-diabetes. BMJ Open 7, e017184 (2017).</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_2dZzDNX">Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the community preventive services task force</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_gpTZbTc">Ann. Intern. Med</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="452" to="460" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, R. et al. Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a sys- tematic review for the community preventive services task force. Ann. Intern. Med. 163, 452-460 (2015).</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_2xrbtYw">Cost-effectiveness analysis of a school-and community-based intervention to promote a healthy lifestyle and prevent type 2 diabetes in vulnerable families across Europe: the Feel4Diabetes-study</title>
		<author>
			<persName><forename type="first">R</forename><surname>Willems</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jk5C5cd">Prev. Med</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page">106722</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Willems, R. et al. Cost-effectiveness analysis of a school-and community-based intervention to promote a healthy lifestyle and prevent type 2 diabetes in vul- nerable families across Europe: the Feel4Diabetes-study. Prev. Med. 153, 106722 (2021).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_5cRCRyg">Can mobile health technologies transform health care?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Steinhubl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Muse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Topol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Yr88zhp">JAMA</title>
		<imprint>
			<biblScope unit="volume">310</biblScope>
			<biblScope unit="page" from="2395" to="2396" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Steinhubl, S. R., Muse, E. D. &amp; Topol, E. J. Can mobile health technologies trans- form health care? JAMA 310, 2395-2396 (2013).</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<author>
			<persName><surname>Bankmycell</surname></persName>
		</author>
		<author>
			<persName><surname>Com</surname></persName>
		</author>
		<ptr target="https://www.bankmycell.com/blog/how-many-phones-are-in-the-world" />
		<title level="m" xml:id="_tddCrNC">How Many Smartphones are in the World?</title>
		<imprint>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bankmycell.com. How Many Smartphones are in the World? https:// www.bankmycell.com/blog/how-many-phones-are-in-the-world (2022).</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_DCreZrV">A systematic review of mobile health technologies to support self-management of concurrent diabetes and hypertension</title>
		<author>
			<persName><forename type="first">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.1093/jamia/ocaa029</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_s9xApFt">J. Am. Med Inf. Assoc</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="939" to="945" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Choi, W., Wang, S., Lee, Y., Oh, H. &amp; Zheng, Z. A systematic review of mobile health technologies to support self-management of concurrent diabetes and hypertension. J. Am. Med Inf. Assoc. 27, 939-945 (2020).</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_sm2mXGG">Clinical-and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and metaanalysis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<idno type="DOI">10.1097/md.0000000000000312</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rWMzaj5">Med. (U. S.)</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page">312</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhai, Y. K., Zhu, W. J., Cai, Y. L., Sun, D. X. &amp; Zhao, J. Clinical-and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta- analysis. Med. (U. S.) 93, e312 (2014).</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_ksKg3dc">Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.2196/15400</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_33aNT9R">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">15400</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wang, Y. et al. Effectiveness of mobile health interventions on diabetes and obesity treatment and management: systematic review of systematic reviews. JMIR Mhealth Uhealth 8, e15400 (2020).</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_t4gYQHA">The effectiveness of self-management of hypertension in adults using mobile health: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hesketh</surname></persName>
		</author>
		<idno type="DOI">10.2196/17776</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TJ3w2Ay">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">17776</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, R., Liang, N., Bu, F. &amp; Hesketh, T. The effectiveness of self-management of hypertension in adults using mobile health: systematic review and meta-analysis. JMIR Mhealth Uhealth 8, e17776 (2020).</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_bYhv4ds">Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Khoong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wPjjM4y">NPJ Digit. Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">114</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khoong, E. C. et al. Mobile health strategies for blood pressure self-management in urban populations with digital barriers: systematic review and meta-analyses. NPJ Digit. Med. 4, 114 (2021).</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_XPVKxv5">Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with type 2 diabetes: A systematic literature review and meta-analysis of randomised controlled trials</title>
		<author>
			<persName><forename type="first">G</forename><surname>Moschonis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EkN9xrh">Lancet Digit. Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="125" to="e143" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moschonis, G. et al. Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with type 2 diabetes: A systematic literature review and meta-analysis of randomised controlled trials. Lancet Digit. Health 5, e125-e143 (2023).</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_cXYaB8a">Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with hypertension: A systematic literature review and meta-analysis of randomised controlled trials</title>
		<author>
			<persName><forename type="first">G</forename><surname>Siopis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9TjRtNy">Lancet Digit. Health</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="144" to="e159" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Siopis, G. et al. Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with hypertension: A systematic literature review and meta-analysis of randomised controlled trials. Lancet Digit. Health 5, e144-e159 (2023).</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_ab3AAnC">mHealth: new horizons for health mobile technologies: based on the second global survey on eHealth</title>
		<author>
			<persName><surname>Who</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_kA5Xhz4">Global Observatory for eHealth</title>
		<meeting><address><addrLine>Geneva</addrLine></address></meeting>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2011">2011</date>
			<biblScope unit="volume">3</biblScope>
		</imprint>
	</monogr>
	<note type="raw_reference">WHO. mHealth: new horizons for health mobile technologies: based on the second global survey on eHealth. in Global Observatory for eHealth, Vol. 3 (World Health Organization, Geneva, 2011).</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_Tk99Rvx">What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Iribarren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Falzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Stone</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0170581</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EjNjHSv">PloS One</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">170581</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Iribarren, S. J., Cato, K., Falzon, L. &amp; Stone, P. W. What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions. PloS One 12, e0170581 (2017).</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_jA7tKMJ">Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: a systematic review</title>
		<author>
			<persName><forename type="first">G</forename><surname>Rinaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hijazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haghparast-Bidgoli</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.diabres.2020.108084</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_umk5UB2">Diabetes Res. Clin. Pract</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page">108084</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rinaldi, G., Hijazi, A. &amp; Haghparast-Bidgoli, H. Cost and cost-effectiveness of mHealth interventions for the prevention and control of type 2 diabetes mellitus: a systematic review. Diabetes Res. Clin. Pract. 162, 108084 (2020).</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_GdQzSU9">The impact of digital health interventions for the management of type 2 diabetes on health and social care utilisation and costs: a systematic review</title>
		<author>
			<persName><forename type="first">T</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Aspinal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ledger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gomes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_grjxAKD">Pharmacoecon Open</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="163" to="173" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Morris, T., Aspinal, F., Ledger, J., Li, K. &amp; Gomes, M. The impact of digital health interventions for the management of type 2 diabetes on health and social care utilisation and costs: a systematic review. Pharmacoecon Open 7, 163-173 (2022).</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_ShcjwZ3">How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Wijnen</surname></persName>
		</author>
		<idno type="DOI">10.1080/14737167.2016.1246961</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_spw9YVQ">Expert Rev. Pharmacoecon. Outcomes Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="723" to="732" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wijnen, B. et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). Expert Rev. Pharmacoecon. Outcomes Res. 16, 723-732 (2016).</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_VbmMpjw">Clinical and economic impact of a digital, remotely-delivered intensive behavioral counseling program on medicare beneficiariesat risk for diabetes and cardiovascular disease</title>
		<author>
			<persName><forename type="first">F</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0163627</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ugc89fE">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">163627</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chen, F. et al. Clinical and economic impact of a digital, remotely-delivered intensive behavioral counseling program on medicare beneficiariesat risk for diabetes and cardiovascular disease. PLoS One 11, e0163627 (2016).</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_7eQzYmS">Cost-effectiveness of facilitated access to a self-management website, compared to usual Care, for patients with type 2 diabetes (HeLP-diabetes): randomized controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uKZUpCV">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, J. et al. Cost-effectiveness of facilitated access to a self-management website, compared to usual Care, for patients with type 2 diabetes (HeLP-diabetes): ran- domized controlled trial. J. Med. Internet Res. 20, 1-15 (2018).</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_Rcg8V83">Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mcmanus</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.m2216</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vJBQY2p">BMJ</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page">4858</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McManus, R. J. et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hyperten- sion: randomised controlled trial. BMJ 372, m4858 (2021).</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_eC2knVn">Cost-utility of an online education platform and diabetes personal health record: analysis over ten years</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zwFnN7e">J. Diabetes Sci. Technol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="715" to="726" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cunningham, S. G. et al. Cost-utility of an online education platform and diabetes personal health record: analysis over ten years. J. Diabetes Sci. Technol. 17, 715-726 (2022).</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_twm52gs">Cost-effectiveness analysis of group vs. Weblog Telecommunication (Web Tel) nutrition education program on glycemic indices in patients with non-insulin dependent diabetes mellitus type 2: a randomized controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Derakhshandeh-Rishehri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Keshavarz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ghodsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pishdad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faghih</surname></persName>
		</author>
		<idno type="DOI">10.3389/fnut.2022.915847</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wNQWwvZ">Front. Nutr</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">915847</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Derakhshandeh-Rishehri, S. M., Keshavarz, K., Ghodsi, D., Pishdad, G. &amp; Faghih, S. Cost-effectiveness analysis of group vs. Weblog Telecommunication (Web Tel) nutrition education program on glycemic indices in patients with non-insulin dependent diabetes mellitus type 2: a randomized controlled trial. Front. Nutr. 9, 915847 (2022).</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_CmqeVx3">Cost-effectiveness of a comprehensive approach for hypertension control in low-income settings in Argentina: trial-based analysis of the hypertension control program in Argentina</title>
		<author>
			<persName><forename type="first">F</forename><surname>Augustovski</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2018.06.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uS5pzdy">Value Health</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1357" to="1364" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Augustovski, F. et al. Cost-effectiveness of a comprehensive approach for hypertension control in low-income settings in Argentina: trial-based analysis of the hypertension control program in Argentina. Value Health 21, 1357-1364 (2018).</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_8FM9jbs">Costeffectiveness of a technology-enhanced diabetes care management program in Mexico</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gilmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Burgos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Anzaldo-Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vargas-Ojeda</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.vhri.2018.12.006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZRcM2sT">Value Health Reg. Issues</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="41" to="46" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gilmer, T., Burgos, J. L., Anzaldo-Campos, M. C. &amp; Vargas-Ojeda, A. Cost- effectiveness of a technology-enhanced diabetes care management program in Mexico. Value Health Reg. Issues 20, 41-46 (2019).</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_v377pfr">Cost-effectiveness of a mobile-phone text messaging intervention on type 2 diabetes-a randomized-controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M S</forename><surname>Islam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_nUeEJuw">Health Policy Technol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="79" to="85" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Islam, S. M. S. et al. Cost-effectiveness of a mobile-phone text messaging inter- vention on type 2 diabetes-a randomized-controlled trial. Health Policy Technol. 9, 79-85 (2020).</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_zbHca2A">Cost-effectiveness of a short message service intervention to prevent type 2 diabetes from impaired glucose tolerance</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_meT4h4g">J. Diabetes Res</title>
		<imprint>
			<biblScope unit="page">1219581</biblScope>
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wong, C. K. et al. Cost-effectiveness of a short message service intervention to prevent type 2 diabetes from impaired glucose tolerance. J. Diabetes Res. 2016, 1219581 (2016).</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_kpQ8Qcq">Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Faleh Almutairi</surname></persName>
		</author>
		<idno type="DOI">10.1177/204062232110425</idno>
		<ptr target="https://doi.org/10.1177/204062232110425" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_Jgnfdx3">Ther. Adv. Chronic Dis</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Faleh AlMutairi, M. et al. Cost-effectiveness of telemedicine care for patients with uncontrolled type 2 diabetes mellitus during the COVID-19 pandemic in Saudi Arabia. Ther. Adv. Chronic Dis. https://doi.org/10.1177/204062232110425 (2021).</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_YjR32Py">Cost-effectiveness of a multicomponent Iintervention for hypertension control in low-income settings in Argentina</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Nc8J7Jt">JAMA Netw. Open</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">2122559</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhang, Y. et al. Cost-effectiveness of a multicomponent Iintervention for hyper- tension control in low-income settings in Argentina. JAMA Netw. Open 4, e2122559 (2021).</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_fpBMU3m">Cost-effectiveness of a continuous glucose monitoring mobile app for patients with type 2 diabetes mellitus: analysis simulation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tsuji</surname></persName>
		</author>
		<idno type="DOI">10.2196/16053</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_cvpPTTk">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">16053</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tsuji, S. et al. Cost-effectiveness of a continuous glucose monitoring mobile app for patients with type 2 diabetes mellitus: analysis simulation. J. Med. Internet Res. 22, e16053 (2020).</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_PA2a2tc">Cost-effectiveness analysis of different hypertension management strategies in a community setting</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11739-019-02146-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EM62HTG">Intern. Emerg. Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="241" to="250" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhang, X. et al. Cost-effectiveness analysis of different hypertension management strategies in a community setting. Intern. Emerg. Med. 15, 241-250 (2020).</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_tYxgJVv">Cost-effectiveness analysis of a mobile-based intervention for patients with type 2 diabetes mellitus</title>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KdPrrWv">Int. J. Endocrinol</title>
		<imprint>
			<biblScope unit="page">8827629</biblScope>
			<date type="published" when="2021">2021. 2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Li, J., Sun, L., Hou, Y. &amp; Chen, L. Cost-effectiveness analysis of a mobile-based intervention for patients with type 2 diabetes mellitus. Int. J. Endocrinol. 2021, 8827629 (2021).</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_2YkswA9">Time to remove hypertension from our vocabulary?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wells</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(21)01916-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xvyJb53">Lancet (Lond., Engl.)</title>
		<imprint>
			<biblScope unit="volume">398</biblScope>
			<biblScope unit="page" from="1023" to="1025" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jackson, R. &amp; Wells, S. Time to remove hypertension from our vocabulary? Lancet (Lond., Engl.) 398, 1023-1025 (2021).</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_hhqgqvs">Is the concept of hypertension as a disease unhelpful?</title>
		<author>
			<persName><forename type="first">L</forename><surname>The</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_57Aq9GW">Lancet (Lond., Engl.)</title>
		<imprint>
			<biblScope unit="volume">394</biblScope>
			<biblScope unit="page">611</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">The, L. Is the concept of hypertension as a disease unhelpful? Lancet (Lond., Engl.) 394, 611 (2019).</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_hWe7BaK">Using new technologies to improve the prevention and management of chronic conditions in populations</title>
		<author>
			<persName><forename type="first">B</forename><surname>Oldenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>O'neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cocker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Cameron</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev-publhealth-031914-122848</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TJdvaTR">Annu Rev. Public Health</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="483" to="505" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Oldenburg, B., Taylor, C. B., O&apos;Neil, A., Cocker, F. &amp; Cameron, L. D. Using new technologies to improve the prevention and management of chronic conditions in populations. Annu Rev. Public Health 36, 483-505 (2015).</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_bXrfNeb">Mobile apps for increasing treatment adherence: systematic review</title>
		<author>
			<persName><forename type="first">V</forename><surname>Pérez-Jover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sala-González</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guilabert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mira</surname></persName>
		</author>
		<idno type="DOI">10.2196/12505</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yKzHJVX">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">12505</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pérez-Jover, V., Sala-González, M., Guilabert, M. &amp; Mira, J. J. Mobile apps for increasing treatment adherence: systematic review. J. Med. Internet Res. 21, e12505 (2019).</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_KwfTqCs">Rates of attrition and dropout in app-based interventions for chronic disease: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Meyerowitz-Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7cxTGVc">J. Med. Internet Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">20283</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Meyerowitz-Katz, G. et al. Rates of attrition and dropout in app-based interven- tions for chronic disease: systematic review and meta-analysis. J. Med. Internet Res. 22, e20283 (2020).</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_ETAQVZj">Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Jabardo-Camprubí</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Donat-Roca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sitjà-Rabert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Milà-Villarroel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bort-Roig</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.physbeh.2019.112786</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pZjeHaP">Physiol. Behav</title>
		<imprint>
			<biblScope unit="volume">215</biblScope>
			<biblScope unit="page">112786</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Jabardo-Camprubí, G., Donat-Roca, R., Sitjà-Rabert, M., Milà-Villarroel, R. &amp; Bort- Roig, J. Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: a systematic review and meta-analysis. Physiol. Behav. 215, 112786 (2020).</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_fPVvbdG">Co-design of mHealth delivered interventions: a systematic review to assess key methods and processes</title>
		<author>
			<persName><forename type="first">H</forename><surname>Eyles</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13668-016-0165-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fVaErx9">Curr. Nutr. Rep</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="160" to="167" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Eyles, H. et al. Co-design of mHealth delivered interventions: a systematic review to assess key methods and processes. Curr. Nutr. Rep. 5, 160-167 (2016).</note>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<author>
			<orgName type="collaboration">WHO</orgName>
		</author>
		<title level="m" xml:id="_WzKU3tD">Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development</title>
		<meeting><address><addrLine>Geneva</addrLine></address></meeting>
		<imprint>
			<publisher>World Health Organization</publisher>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">WHO. Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development (World Health Organization, Gen- eva, 2001).</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_EprsgYh">Cost-effectiveness thresholds: pros and cons</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Bertram</surname></persName>
		</author>
		<idno type="DOI">10.2471/blt.15.164418</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5VXVZsJ">Bull. World Health Organ</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="925" to="930" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bertram, M. Y. et al. Cost-effectiveness thresholds: pros and cons. Bull. World Health Organ. 94, 925-930 (2016).</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_Gk3by9k">Country-level cost-effectiveness thresholds: initial estimates and the need for further research</title>
		<author>
			<persName><forename type="first">B</forename><surname>Woods</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Revill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sculpher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Claxton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_A2adwYJ">Value Health</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="929" to="935" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Woods, B., Revill, P., Sculpher, M. &amp; Claxton, K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health 19, 929-935 (2016).</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_8eyjxE5">Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Lawrence</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2021.11165</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RDpakPJ">JAMA</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="page" from="717" to="727" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lawrence, J. M. et al. Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA 326, 717-727 (2021).</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_hwp48wS">Global prevalence of hypertension in children: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Song</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ewdPV2x">JAMA Pediatr</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="page" from="1154" to="1163" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Song, P. et al. Global prevalence of hypertension in children: a systematic review and meta-analysis. JAMA Pediatr. 173, 1154-1163 (2019).</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_y3QnUpQ">Prevalence and determinants of hypertension in India based on the 2017 ACC/AHA guideline: evidence from the India National Family Health Survey</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Abariga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Khachan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Al Kibria</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MJwzQRv">Am. J. Hypertens</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="252" to="260" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Abariga, S. A., Khachan, H. &amp; Al Kibria, G. M. Prevalence and determinants of hypertension in India based on the 2017 ACC/AHA guideline: evidence from the India National Family Health Survey. Am. J. Hypertens. 33, 252-260 (2020).</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_gxnh3Eu">Estimating lifetime risk of diabetes in the Chinese population</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bragg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9QFbGT6">PLoS Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">1004053</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bragg, F. &amp; Chen, Z. Estimating lifetime risk of diabetes in the Chinese population. PLoS Med. 19, e1004053 (2022).</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_bAF2sfK">Critical appraisal of systematic reviews with costs and costeffectiveness outcomes: an ISPOR good practices task force report</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">L</forename><surname>Mandrik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BY9HhPE">Value Health</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="463" to="472" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mandrik, O. L. et al. Critical appraisal of systematic reviews with costs and cost- effectiveness outcomes: an ISPOR good practices task force report. Value Health 24, 463-472 (2021).</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_zbuQ54v">Cost-effectiveness analysis alongside clinical trials II-An ISPOR good research practices task force report</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Ramsey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Qpm6X7T">Value Health</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="161" to="172" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramsey, S. D. et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR good research practices task force report. Value Health 18, 161-172 (2015).</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_yTQnMxm">The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NFqPeNJ">BMJ</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page">71</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).</note>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><surname>Werbrouck</surname></persName>
		</author>
		<idno type="DOI">10.1002/9780470750568.ch8</idno>
		<title level="m" xml:id="_svA49mA">Disease prevention and health promotion in Flanders : health economic evidence to support healthcare decision making</title>
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
		<respStmt>
			<orgName>Ghent University and University of Leuven</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Werbrouck, A. Disease prevention and health promotion in Flanders : health economic evidence to support healthcare decision making. (Ghent University and University of Leuven, 2021).</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_CwZwUdc">Search MEDLINE for economic evaluations: tips to translate an OVID strategy into a PubMed one</title>
		<author>
			<persName><forename type="first">M</forename><surname>Neyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">X</forename><surname>Chalon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JtaqwYj">PharmacoEconomics</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="1087" to="1090" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Neyt, M. &amp; Chalon, P. X. Search MEDLINE for economic evaluations: tips to translate an OVID strategy into a PubMed one. PharmacoEconomics 31, 1087-1090 (2013).</note>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title level="m" xml:id="_SHZmTeT">Search Strategies</title>
		<imprint>
			<date type="published" when="2018">2018</date>
		</imprint>
		<respStmt>
			<orgName>University of York ; University of York</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">University of York. Search Strategies (University of York, 2018).</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_Q5yTZJ9">Rayyan-a web and mobile app for systematic reviews</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ouzzani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hammady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Fedorowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Elmagarmid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Mt2vaQP">Syst. Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">210</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ouzzani, M., Hammady, H., Fedorowicz, Z. &amp; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 5, 210 (2016).</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_4TBSxUn">How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Van Mastrigt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7NWhr4m">Expert Rev. Pharmacoecon. Outcomes Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="689" to="704" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">van Mastrigt, G. A. et al. How to prepare a systematic review of economic eva- luations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev. Pharmacoecon. Outcomes Res. 16, 689-704 (2016).</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_fq9VzmV">Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria</title>
		<author>
			<persName><forename type="first">S</forename><surname>Evers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goossens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>De Vet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Tulder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ament</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wUerqND">Int. J. Technol. Assess. Health Care</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="240" to="245" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Evers, S., Goossens, M., de Vet, H., van Tulder, M. &amp; Ament, A. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int. J. Technol. Assess. Health Care 21, 240-245 (2005).</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<author>
			<persName><surname>You Ruben Willems 1 ✉</surname></persName>
			<affiliation>
				<orgName type="collaboration">DIGICARE</orgName>
			</affiliation>
		</author>
	</analytic>
	<monogr>
		<title level="m" xml:id="_NBX8UY4">Konstantinos Makrilakis 15</title>
		<editor>
			<persName><forename type="first">Sabine</forename><surname>Dupont 18</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Leo</forename><surname>Lewis 19</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Djordje</forename><surname>Djokic</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Helen</forename><surname>Skouteris</surname></persName>
		</editor>
		<imprint>
			<date>10. 17. 21</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">12</biblScope>
		</imprint>
	</monogr>
	<note>George Siopis Florian Toti 14</note>
	<note type="raw_reference">DIGICARE 4YOU Ruben Willems 1 ✉ , Lieven Annemans 1 , George Siopis 2,3 , George Moschonis 2 , Rajesh Vedanthan 4 , Jenny Jung 5 , Dominika Kwasnicka 6,7 , Brian Oldenburg 6 , Claudia d&apos;Antonio 8 , Sandro Girolami 8 , Eirini Agapidaki 9 , Yannis Manios 10,11 , Nick Verhaeghe 1 , Natalya Usheva 12 , Violeta Iotova 12 , Andreas Triantafyllidis 13 , Konstantinos Votis 13 , Florian Toti 14 , Konstantinos Makrilakis 15 , Chiara Seghieri 16 , Luis Moreno 17 , Sabine Dupont 18 , Leo Lewis 19 , Djordje Djokic 20 and Helen Skouteris 21 12</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
